Asking the challenging question, “How do we involve our patients and do they understand what we are saying?”, the researchers took all Dutch decision aids that are available for urological patients and looked at the quality of their clearness in informing patients. There were 13 decision aids in total, of which 4 had an Easy Read quality mark supposedly ensuring patient-friendly language. The texts were analysed, validated with software, and then scored for complexity; level 1 being the easiest (travel blog level) to level 4 being the hardest (scholarly article level). The difficulty of most of these aids landed between level 2 and 3. Their data showed that university-educated people could understand about 80% of aids that scored a 1; whereas people with a lower level of education only understood about 50%. In a decision aid scoring a 4, fewer than 10% of the text was comprehensible to people with an average education. The overwhelming conclusion was that most decision aids in the Netherlands are too difficult to understand for most of our patients, and extrapolating, this may even be a bigger problem in other countries.
Posted on
Previous Article
« Discordance of biomarkers in multifocal and lymph node positive breast cancer Next Article
Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer »
« Discordance of biomarkers in multifocal and lymph node positive breast cancer Next Article
Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer »
Table of Contents: EAU 2019
Featured articles
Prostate Cancer
Barentsz Trial – Bi-parametric MRI versus multi-parametric MRI
Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer
Prostate cancer active surveillance: Better patient risk stratification and use of imaging
The role of pelvic lymph node dissection in prostate cancer: Extended vs standard
When to use imaging and imaging-guided therapies
Radioguided surgery is the future?
Bladder Cancer
Largest safety study of its kind with atezolizumab in metastatic bladder cancer
Bladder cancer risk and early detection
Consensus treatment pathway for patients with limited pelvic lymph node involvement in otherwise localised bladder cancer
FGFR3 gene mutation: Favourable prognostic impact in bladder cancer
Bladder cancer in young patients
Spanish study directly links surgical volume with mortality in bladder cancer patients undergoing cystectomy
Updated interim results of phase 2 trial of pembrolizumab for high-risk NMIBC unresponsive to BCG
Robot-assisted radical cystectomy or open radical cystectomy?
Renal Transplantation and Renal Cell Carcinoma
Andrology
Microdissection testicular sperm extraction (microTESE)
Male infertility/Premature ejaculation
Testosterone replacement therapy: Safe and maybe even protective
Focus on treatment of erectile dysfunction and Peyronie’s disease
Penile prosthesis implantation
Functional Urology
Decision aids are too difficult for patients
Lower Urinary Tract Symptoms
The Urodynamics for Prostate Surgery Trial
Minimally invasive surgical techniques must compete against pharmacotherapy in benign prostate hyperplasia (BPH)
Related Articles
February 13, 2021
Details released for CLEAR study on advanced renal cell carcinoma
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com